"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
"C.I.Parhon" National Institute of Endocrinology, Bd. Aviatorilor, no. 34-36, sector 1, 011863, Bucharest, Romania.
Hormones (Athens). 2024 Mar;23(1):107-111. doi: 10.1007/s42000-023-00496-w. Epub 2023 Oct 13.
We present two cases of autoimmune hypothyroidism converted to Graves' disease (GD) and their medical management.
We tested thyroid function and thyroid antibodies and performed an ophthalmologic examination and neck ultrasound in two patients with autoimmune hypothyroidism converted to GD during a follow-up of several years.
The first case is a 33 year-old woman with hypothyroidism due to Hashimoto's thyroiditis (HT). She developed signs and symptoms of hyperthyroidism after 7 years of treatment with the same dose of levothyroxine (LT). Even when LT therapy was discontinued, she remained thyrotoxic, with mild Graves' ophthalmopathy (GO) and very high thyroid-stimulating hormone receptor antibodies (TRAb > 40 IU/L, reference range: <1.75 IU/L). Antithyroid medication was started on a titration regimen, without achievement of euthyroidism. She was switched to a block and replace regimen, using 20 mg of methimazole (MMI) and 75 mcg of LT daily, with normalization of thyroid hormones and improvement of GO without steroids. The second case is a 57 year-old man with a 2-year positive medical history of HT and 6 months of LT treatment. He developed hyperthyroidism and moderate-severe GO. Despite stopping LT and initiating antithyroid medication in a titration regimen, he did not achieve euthyroidism and had active GO. Pulse glucocorticoid therapy and switching to a block-replace regimen was required to achieve euthyroidism and reduce ocular proptosis and diplopia.
Spontaneous autoimmune conversion of hypothyroidism to hyperthyroidism can occur at any time: it is important to promptly identify these cases so as to manage them effectively.
我们报告了两例自身免疫性甲状腺功能减退症(甲减)转化为格雷夫斯病(GD)的病例及其治疗。
我们对两名在多年随访中出现甲减转化为 GD 的患者进行了甲状腺功能和甲状腺抗体检测,以及眼科检查和颈部超声检查。
第一例是一位 33 岁的女性,患有桥本甲状腺炎(HT)导致的甲减。在接受左甲状腺素(LT)治疗 7 年后,她出现了甲亢的症状和体征。即使停止 LT 治疗,她仍处于甲状腺毒症状态,轻度格雷夫斯眼病(GO)和非常高的促甲状腺激素受体抗体(TRAb > 40 IU/L,参考范围:<1.75 IU/L)。开始使用抗甲状腺药物进行滴定方案治疗,但未达到甲状腺功能正常。她转为阻断-替代方案,每日使用 20 mg 甲巯咪唑(MMI)和 75 mcg LT,甲状腺激素正常化,GO 改善,无需使用类固醇。第二例是一位 57 岁男性,患有 HT 病史 2 年,LT 治疗 6 个月。他出现了甲亢和中度重度 GO。尽管停止 LT 并开始抗甲状腺药物滴定方案治疗,但他仍未达到甲状腺功能正常,GO 仍活跃。需要脉冲糖皮质激素治疗和转为阻断-替代方案,才能达到甲状腺功能正常并减少眼球突出和复视。
自身免疫性甲减向甲亢的自发转化可随时发生:及时识别这些病例并进行有效治疗非常重要。